SCHEMBL305274

SCHEMBL305274

CCOC(=O)CCc1ccc(O[Si](C)(C)C(C)(C)C)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.57
CYP4A11 Q02928 2/20 0.57
DRD2 P14416 1/20 0.52
CYP4Z1 Q86W10 2/20 0.47
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
EPHX2 P34913 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
PKM P14618 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
P2RY12 Q9H244 1/20 0.40
PREP P48147 1/20 0.40
CYP4F11 Q9HBI6 1/20 0.40
CYP4F12 Q9HCS2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7535671 0.86 F2RL1 (0.46) CYP4F2CYP4A11DRD2LMNAMAPT
SCHEMBL305427 0.84 TDP1 (0.50) LMNAMAPTL3MBTL1TDP1
SCHEMBL2890795 0.83 FFAR1 (0.47) CYP4F2CYP4A11DRD2TDP1
SCHEMBL4000606 0.82 LMNA (0.48) DRD2LMNAMAPTL3MBTL1PREP
SCHEMBL4266308 0.82 FFAR1 (0.53) LMNAL3MBTL1
SCHEMBL4261600 0.81 PREP (0.42) LMNAL3MBTL1PREP
SCHEMBL7254705 0.81 DRD2 (0.74) CYP4F2CYP4A11DRD2LMNAPDE3B
SCHEMBL68902 0.80 CYP4F2 (0.85) CYP4F2CYP4A11CYP4Z1LMNAMAPT
SCHEMBL9138459 0.78 CYP4Z1 (0.46) CYP4F2CYP4A11DRD2CYP4Z1TDP1
SCHEMBL1741166 0.78 THRB (0.42) DRD2LMNAL3MBTL1PREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12251370-B2 Small molecule inhibitors of the BfrB:Bfd interaction BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2025-03-18 US disclosed
US-20220031661-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION UNIVERSITY OF KANSAS 2022-02-03 US disclosed
US-20220031661-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION UNIVERSITY OF KANSAS 2022-02-03 US disclosed
WO-2020117832-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION UNIVERSITY OF KANSAS (US) 2020-06-11 WO disclosed
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS MEIJI SEIKA KAISHA (JP) 2016-06-02 US disclosed
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS MEIJI SEIKA KAISHA (JP) 2016-06-02 US disclosed
US-9260375-B2 Metallo-β-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2016-02-16 US disclosed
US-9260375-B2 Metallo-β-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2016-02-16 US disclosed
US-9260375-B2 Metallo-β-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2016-02-16 US disclosed
US-20120071457-A1 METALLO-BETA-LACTAMASE INHIBITORS CHIKAUCHI KEN (JP) 2012-03-22 US disclosed
US-20120071457-A1 METALLO-BETA-LACTAMASE INHIBITORS CHIKAUCHI KEN (JP) 2012-03-22 US disclosed
US-8093294-B2 Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2012-01-10 US disclosed
US-8093294-B2 Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2012-01-10 US disclosed
EP-1941873-A1 METALLO-BETA-LACTAMASE INHIBITOR MEIJI SEIKA KAISHA LTD. (JP) 2008-07-09 EP disclosed
US-20080090825-A1 Metallo-beta-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-17 US disclosed
US-20080090825-A1 Metallo-beta-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090825-A1 Metallo-beta-lactamase inhibitors ME1, MGAM, GAA CYP4F2 1625/4885CYP4A11 1497/4885DRD2 4635/4885
US-12251370-B2 Small molecule inhibitors of the BfrB:Bfd interaction BLVRB, TFPI, ETFB CYP4F2 242/4885CYP4A11 3088/4885DRD2 2418/4885
US-20120071457-A1 METALLO-BETA-LACTAMASE INHIBITORS ME1, MGAM, GAA CYP4F2 1625/4885CYP4A11 1497/4885DRD2 4635/4885
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS ME1, MGAM, MANBA CYP4F2 1614/4885CYP4A11 1459/4885DRD2 4668/4885
US-20220031661-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION BLVRB, TFPI, ETFB CYP4F2 242/4885CYP4A11 3088/4885DRD2 2418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.